Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + lazertinib + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of amivantamab, a bispecific antibody targeting EGFR and MET; lazertinib, a third-generation EGFR tyrosine kinase inhibitor; and pemetrexed, a folate antimetabolite chemotherapy. It is being investigated as a first-line treatment for patients with recurrent or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations, specifically exon 19 deletions or L858R point mutations. The regimen aims to provide comprehensive inhibition of the EGFR and MET pathways while utilizing cytotoxic chemotherapy to overcome or delay resistance. The Latin American Cooperative Oncology Group (LACOG) is the lead sponsor for the Phase 2 trial (LACOG-0121) evaluating this triplet regimen.
- Other names
- Amivantamab, Lazertinib, and Pemetrexed combinationLACOG-0121 regimenLACOG0121 regimenLACOG 0121 regimen
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)EGFR (Epidermal growth factor receptor)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on amivantamab + lazertinib + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + lazertinib + pemetrexed.